

ANI PHARMACEUTICALS INC  
Form 8-K  
October 13, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 12, 2015**

**ANI PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-31812</b> (Commission File Number)	<b>58-2301143</b> (I.R.S. Employer Identification Number)
--	--	---

**210 Main Street West  
Baudette, Minnesota**

**56623**

Edgar Filing: ANI PHARMACEUTICALS INC - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(218) 634-3500**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

- Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

*Election of New Director*

On October 12, 2015, Peter A. Lankau was appointed as a director to fill the existing vacancy in the Board of Directors (the "Board") of ANI Pharmaceuticals, Inc. (the "Company" or "ANI"). Mr. Lankau will serve as a director until the Company's 2016 Annual Meeting of Stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Lankau will also serve as a member of the Board's Compensation Committee and Nominating and Corporate Governance Committee. Upon Mr. Lankau's appointment, the Board is comprised of a majority of independent directors and the Company meets the independent director requirements set forth in Nasdaq Listing Rule 5605.

On October 13, 2015, the Company issued a press release announcing the appointment of Mr. Lankau to the Board. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**No. Description**

99.1 Press release, dated October 13, 2015

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANI PHARMACEUTICALS, INC.**

By: /s/ Charlotte C. Arnold

Charlotte C. Arnold

*Vice President, Finance, and Chief Financial Officer*

Dated: October 13, 2015